ArticleCureus2025
Rocuronium-Induced Rhabdomyolysis: A Case Report and Literature Review.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This case report explores the rare association between rocuronium, a non-depolarizing neuromuscular blocker, and rhabdomyolysis, a serious condition characterized by muscle breakdown. We present a case of an elderly patient who developed rhabdomyolysis after receiving intravenous rocuronium for airway spasticity and analgesic sedation. The patient exhibited a significant increase in creatine kinase (CK) levels, consistent with the diagnostic criteria for rhabdomyolysis. Our analysis indicates that rocuronium may have contributed to the development of this condition, especially with prolonged use and suboptimal anesthetic management. We recommend limiting the maintenance dose of rocuronium and closely monitoring patients for signs of muscle injury or elevated CK levels during and after treatment. This case highlights the importance of careful assessment and monitoring when using rocuronium, particularly in vulnerable populations, to mitigate the risk of rhabdomyolysis and other adverse effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.